AMARILLO, Texas, March 9 /PRNewswire/ -- Amarillo Biosciences, Inc.
(Nasdaq: AMAR) today announced that research supported by a licensee of
Amarillo Biosciences, was published in two articles in the March issue of the
Journal of Interferon and Cytokine Research (Volume 19, 1999). These articles
entitled, "Oromucosal Interferon Therapy: Marked Antiviral and Antitumor
Activity" and "Oromucosal Interferon Therapy: Pharmacokinetics and
Pharmacodynamics" support the use of oral interferon in the management of
various viral infections and transplantable tumors. "Although these studies
were conducted in mice, they improve our understanding of the mechanism of
action of oral interferon and point toward possible new human uses of oral
interferon," said Dr. Joseph M. Cummins, President and CEO of Amarillo
Biosciences. "The scientists at the Laboratory of Viral Oncology at the
Institute of Research in Cancer in Villejuif, France have explored a range of
oromucosal doses of different interferons and have identified clinical benefit
with interferon alpha, interferon beta and interferon gamma," noted Kathleen
Kelleher, COO of Amarillo Biosciences.
Amarillo Biosciences, founded in 1984, is a world leader in the
development of oral interferon alpha as a treatment for a variety of
conditions including Sjogren's syndrome, fibromyalgia, opportunistic
infections in patients who are HIV positive, hepatitis B and hepatitis C.
Except for the historical information contained herein, the matters
discussed in this news release are forward-looking statements that involve
risks and uncertainties, including uncertainties related to product
development, uncertainties related to the need for regulatory and other
government approvals, dependence on proprietary technology, uncertainty of
market acceptance of oral interferon alpha or the company's other product
candidates and other risks detailed from time to time in the company's filings
with the Securities and Exchange Commission. In particular, see "Item 1.
Financial Business Risk Factors" of the company's Form 10-KSB for the year
ended Dec. 31, 1997."
SOURCE Amarillo Biosciences, Inc.
 back to top
Related links:
http://www.amacell.com
CONTACT:
Kathleen L. Kelleher, COO and Vice President,
Business Development of Amarillo Biosciences Inc., 806-376-1741,
or email, ABI@AmarBio.com
|
